Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
RNA Therapeutics Market: By Type, By Indication, and Region Forecast 2019-2030
Rna Therapeutics Market size was valued at US$ 4.93 billion in 2023 and is poised to grow at a CAGR of 17.4% from 2024-2030. market is poised to grow at a significant rate due to an increase in the prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in a number of biopharmaceutical and biotechnology industries, a rise in funding for the development of RNA therapeutics from public and private sectors, promising pipeline drugs, and wide range of applications with RNA therapeutics are the major factors that are driving the growth of the global market over the forecast timeframe. Players focusing on innovation of newer products and collaboration strategies to retain market position in the global market.
Study Period
2024-2030Base Year
2023CAGR
17.40%Largest Market
North AmericaFastest Growing Market
North America
Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA therapeutics market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global market over the forecast years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 4.93 billion |
Market CAGR |
17.40% |
By Type |
|
By Indication |
|
By Region |
|
Download Free Sample Report
The rna therapeutics market size was valued at US$ 4.93 billion in 2023 and is set to reach a CAGR of 17.4% from 2024-2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The market key players are: Alnylam Pharmaceuticals, Inc. (USA), Genzyme Corporation (USA), Silence Therapeutics PLC (UK), Quark Pharmaceuticals, Inc. (USA), Cenix BioScience GmbH (Germany), Dicerna Pharmaceuticals, Inc. (USA), ISIS pharmaceuticals, Inc. (USA)
1.Executive Summary |
2.Global RNA Therapeutics Market Introduction |
2.1.Global RNA Therapeutics Market - Taxonomy |
2.2.Global RNA Therapeutics Market - Definitions |
2.2.1.Type |
2.2.2.Indication |
2.2.3.Region |
3.Global RNA Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global RNA Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global RNA Therapeutics Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. siRNA |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. ASO |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. mRNA |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. saRNA |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. miRNA |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. tRNA |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Aptamers |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Others |
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
6.Global RNA Therapeutics Market By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oncology |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Ophthalmic Disorders |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Immunology |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Cardiovascular Disorders |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Infectious Diseases |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Genetic Disorders |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. CNS Disorders |
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
6.8. Others |
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.8.3. Market Opportunity Analysis |
7.Global RNA Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America RNA Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.siRNA |
8.1.2.ASO |
8.1.3.mRNA |
8.1.4.saRNA |
8.1.5.miRNA |
8.1.6.tRNA |
8.1.7.Aptamers |
8.1.8.Others |
8.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Oncology |
8.2.2.Ophthalmic Disorders |
8.2.3.Immunology |
8.2.4.Cardiovascular Disorders |
8.2.5.Infectious Diseases |
8.2.6.Genetic Disorders |
8.2.7.CNS Disorders |
8.2.8.Others |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe RNA Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.siRNA |
9.1.2.ASO |
9.1.3.mRNA |
9.1.4.saRNA |
9.1.5.miRNA |
9.1.6.tRNA |
9.1.7.Aptamers |
9.1.8.Others |
9.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oncology |
9.2.2.Ophthalmic Disorders |
9.2.3.Immunology |
9.2.4.Cardiovascular Disorders |
9.2.5.Infectious Diseases |
9.2.6.Genetic Disorders |
9.2.7.CNS Disorders |
9.2.8.Others |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) RNA Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.siRNA |
10.1.2.ASO |
10.1.3.mRNA |
10.1.4.saRNA |
10.1.5.miRNA |
10.1.6.tRNA |
10.1.7.Aptamers |
10.1.8.Others |
10.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oncology |
10.2.2.Ophthalmic Disorders |
10.2.3.Immunology |
10.2.4.Cardiovascular Disorders |
10.2.5.Infectious Diseases |
10.2.6.Genetic Disorders |
10.2.7.CNS Disorders |
10.2.8.Others |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) RNA Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.siRNA |
11.1.2.ASO |
11.1.3.mRNA |
11.1.4.saRNA |
11.1.5.miRNA |
11.1.6.tRNA |
11.1.7.Aptamers |
11.1.8.Others |
11.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oncology |
11.2.2.Ophthalmic Disorders |
11.2.3.Immunology |
11.2.4.Cardiovascular Disorders |
11.2.5.Infectious Diseases |
11.2.6.Genetic Disorders |
11.2.7.CNS Disorders |
11.2.8.Others |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America RNA Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.siRNA |
12.1.2.ASO |
12.1.3.mRNA |
12.1.4.saRNA |
12.1.5.miRNA |
12.1.6.tRNA |
12.1.7.Aptamers |
12.1.8.Others |
12.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oncology |
12.2.2.Ophthalmic Disorders |
12.2.3.Immunology |
12.2.4.Cardiovascular Disorders |
12.2.5.Infectious Diseases |
12.2.6.Genetic Disorders |
12.2.7.CNS Disorders |
12.2.8.Others |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Moderna Therapeutics, Inc. |
13.2.2.Alnylam Pharamceuticals, Inc. |
13.2.3.Arbutus Biopharma Corp |
13.2.4.Sylentis S.A. |
13.2.5.Santaris Pharma A/S. |
13.2.6.Arrowhead Pharmaceuticals, Inc. |
13.2.7.BioNTech AG |
13.2.8.Regulus Therapeutics, Inc. |
13.2.9.CureVac, AG |
13.2.10.Dicerna Pharmaceuticals, AG |
13.2.11.Marina Biotech, Inc. |
13.2.12.miRagen Therapeutics |
13.2.13.Quark Pharmaceuticals, Inc. |
13.2.14.Pfizer Inc |
14. Research Methodology |
15. Appendix and Abbreviations |
Key Market Players